Pharmacologic treatments for covid-19 patients

Below you can access forest plots for all the treatment comparisons as well as the general characteristics of each trial with risk of bias assessment.

Analyses are updated every Friday.

Of note, the search “display new or updated results” may identify comparisons not tagged as ‘updated’ when a trial related to this comparison has been identified or updated and is reported in the table but is not yet included in the analysis.

More details about outcomes and Disease severity

Specific search

Display all results

Display only new or updated results

Search by treatment name :

Your research: comparisons updated with new studies

Create and download your forest plots with the most up-to-date data here Forest plots

Treatment comparisons

Access the forest plots for the 7 treatment comparisons .

    Anti-virals (2 comparisons)

    Kinase inhibitor (3 comparisons)

    Convalescent plasma (1 comparisons)

    Others (1 comparisons)

General characteristics of primary studies

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
new
NCT04414124
Haran J, medRxiv, 2021
Full text
Commentary
thread Commentary
Private KB109 Standard care RCT Outpatients with confirmed COVID-19 (mild) treated by 16 centers in the USA. N=350
Some concerns
Details

Full description

new
CTRI/2020/06/026087
Pandit A, Int J Infect Dis, 2021
Full text
Commentary
Private Pegylated Interferon alpha-2b Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in India N=40
Some concerns
Details

Full description

new
IRCT20200310046736N1
Pouladzadeh M, Intern Emerg Med, 2021
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran N=62
Some concerns
Details

Full description

new
NCT04402866; EudraCT 2020-001807-18
Singh D, 2021
Full text
Commentary
Commentary
Private TD-0903 1 mg Placebo RCT Patients with confirmed COVID-19 (moderate) admitted to centers in Moldova, UK and Ukraine. N=25
Some concerns
Details

Full description

TD-0903 1 mg TD-0903 3 mg
TD-0903 1 mg TD-0903 10 mg
TD-0903 3 mg Placebo
TD-0903 3 mg TD-0903 10 mg
TD-0903 10 mg Placebo
new
IRCT20200318046812N1
Solaymani-Dodaran M, Int Immunopharmacol, 2021
Full text
Commentary
Public/non profit Favipiravir Lopinavir-Ritonavir RCT Patients with suspected or confirmed COVID-19 (severe) admitted to 20 centers in Iran N=424
Some concerns
Details

Full description